Who are Lotronex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anzemet, Isocain, Bupivacain, Lidocain, Norden, Lamictal.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alosetron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lotronex — Competitive Intelligence Brief

Lotronex (ALOSETRON) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-3 Receptor Antagonist. Area: Neuroscience.

marketed Serotonin-3 Receptor Antagonist 5-hydroxytryptamine receptor 3A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Lotronex (ALOSETRON) — Legacy Pharma. Lotronex works by blocking serotonin receptors in the gut to slow down bowel movements.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lotronex TARGET	ALOSETRON	Legacy Pharma	marketed	Serotonin-3 Receptor Antagonist	5-hydroxytryptamine receptor 3A	2000-01-01
Anzemet	DOLASETRON	Validus Pharms	marketed	Serotonin-3 Receptor Antagonist	5-hydroxytryptamine receptor 3A	1997-01-01
Isocain	PROCAINE	Pfizer	marketed	Amide Local Anesthetic [EPC]	5-hydroxytryptamine receptor 3A	1954-01-01
Bupivacain	Bupivacain	Sisli Hamidiye Etfal Training and Research Hospital	marketed		5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3
Lidocain	Lidocain	Bayer	marketed		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Norden	OCTOPAMINE		marketed	octopamine	5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, Trace amine-associated receptor 1
Lamictal	lamotrigine	GSK	marketed	Anti-epileptic Agent [EPC]	5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-01-07 — Lamictal · 8637512 · Formulation · US
2040-05-29 — Lamictal · 11596634 · Method of Use · US
2040-05-29 — Lamictal · 11612566 · Method of Use · US

Sponsor landscape (Serotonin-3 Receptor Antagonist class)

Legacy Pharma · 1 drug in this class
Validus Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lotronex — Competitive Intelligence Brief. https://druglandscape.com/ci/alosetron. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab